Cargando…

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer

Circulating IL-6, an activator of JAK/STAT signaling, is associated with poor prognosis and aromatase inhibitor (AI) resistance in hormone-receptor positive (HR+) breast cancer. Here we report the results of a phase 2 single-arm Simon 2-stage trial combining Ruxolitinib, an oral selective inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makhlin, Igor, McAndrew, Nicholas P., Wileyto, E. Paul, Clark, Amy S., Holmes, Robin, Bottalico, Lisa N., Mesaros, Clementina, Blair, Ian A., Jeschke, Grace R., Fox, Kevin R., Domchek, Susan M., Matro, Jennifer M., Bradbury, Angela R., Feldman, Michael D., Hexner, Elizabeth O., Bromberg, Jacqueline F., DeMichele, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652412/ https://www.ncbi.nlm.nih.gov/pubmed/36369506 http://dx.doi.org/10.1038/s41523-022-00487-x

Ejemplares similares

Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates
por: Teslenko, Irina, et al.
Publicado: (2022)

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
por: Zilembo, N., et al.
Publicado: (1995)

Effects of systemic inflammation on relapse in early breast cancer
por: McAndrew, Nicholas P., et al.
Publicado: (2021)

Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane
por: Luo, Shaman, et al.
Publicado: (2018)

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
por: Teslenko, Irina, et al.
Publicado: (2022)

Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
por: Lee, June Koo, et al.
Publicado: (2013)

Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti‐aromatase activity assay examining exemestane and its derivatives
por: Peterson, Amity, et al.
Publicado: (2017)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies
por: Chen, Saisai, et al.
Publicado: (2023)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER(+)) Breast Cancer: Effects on Sensitive and Resistant Cell Lines
por: Amaral, Cristina, et al.
Publicado: (2023)

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer(†)
por: O'Shaughnessy, J., et al.
Publicado: (2016)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
por: HOLE, STINE, et al.
Publicado: (2015)

Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors
por: Chim, Kannie, et al.
Publicado: (2013)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors
por: Mao, Jun J, et al.
Publicado: (2011)

Effects of Estrogens on Adipokines and Glucose Homeostasis in Female Aromatase Knockout Mice
por: Van Sinderen, Michelle L., et al.
Publicado: (2015)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

The Aromatase–Estrogen System in the Testes of Non-Mammalian Vertebrates
por: Rosati, Luigi, et al.
Publicado: (2021)

A photo-distributed papulopustular eruption and multiple squamous cell carcinomas in a patient on ruxolitinib
por: Khanna, Urmi, et al.
Publicado: (2019)

Subepithelial Corneal Deposits Associated with Exemestane
por: Amireskandari, Annahita, et al.
Publicado: (2020)

Targeted Chiral Analysis of Bioactive Arachidonic Acid Metabolites Using Liquid-Chromatography-Mass Spectrometry
por: Mesaros, Clementina, et al.
Publicado: (2012)

Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease
por: Mesaros, Clementina, et al.
Publicado: (2016)

Coccidioidomycosis in Patients Treated With Ruxolitinib
por: Kusne, Yael, et al.
Publicado: (2020)

Aromatase expression and role of estrogens in male gonad : a review
por: Carreau, Serge, et al.
Publicado: (2003)

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors
por: Romero, Sally A.D., et al.
Publicado: (2019)

Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?
por: Bauml, Joshua, et al.
Publicado: (2015)

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
por: Miller, Christopher A., et al.
Publicado: (2016)

SUN-125 Phase Ib Study of Dual Therapy with an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women with Advanced Non-Small Cell Lung Cancer
por: Young, Patricia A, et al.
Publicado: (2020)

Exemestane in early breast cancer: a review
por: Untch, Michael, et al.
Publicado: (2008)

Antiproliferative effect of exemestane in lung cancer cells
por: Koutras, Angelos, et al.
Publicado: (2009)

Clinical utility of exemestane in the treatment of breast cancer
por: Zucchini, Giorgia, et al.
Publicado: (2015)

Effects of incubation temperature and estrogen exposure on aromatase activity in the brain and gonads of embryonic alligators.
por: Milnes, Matthew R, et al.
Publicado: (2002)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report
por: Liang, Angela L., et al.
Publicado: (2021)

Aromatase Expression Increases the Survival and Malignancy of Estrogen Receptor Positive Breast Cancer Cells
por: Mukhopadhyay, Keya De, et al.
Publicado: (2015)

Molecular Basis for Endocrine Disruption by Pesticides Targeting Aromatase and Estrogen Receptor
por: Zhang, Chao, et al.
Publicado: (2020)

Estrogen disorders: Interpreting the abnormal regulation of aromatase in granulosa cells (Review)
por: Liu, Ting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b5jmm3uv63gpmfgq9c3mullq1o